FF301 | 47,449,899 | | --- | 第 1 頁 共 7 頁 v 1.0.2 公司名稱: 康希諾生物股份公司 呈交日期: 2023年9月4日 I. 法定/註冊股本變動 證券代號 06185 說明 H 股 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 06185 | 說明 | H 股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | 致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變 ...

康希诺生物股份公司 2023 年第二次临时股东大会及类别股东大会 证券代码：688185 证券简称：康希诺 康希诺生物股份公司 2023 年第二次临时股东大会、 2023 年第二次 A 股类别股东大会及 2023 年第二次 H 股类别股东大会会议资料 2023 年 9 月 康希诺生物股份公司 2023 年第二次临时股东大会及类别股东大会 目录 | 2023 | 年第二次临时股东大会、2023 | 年第二次 | A | 股类别股东大会及 | 2023 | 年第二 | | --- | --- | --- | --- | --- | --- | --- | | 次 H | 股类别股东大会会议须知 1 | | | | | | | 2023 | 年第二次临时股东大会、2023 | 年第二次 | A | 股类别股东大会及 | 2023 | 年第二 | | 次 H | 股类别股东大会会议议程 4 | | | | | | | 2023 | 年第二次临时股东大会、2023 | 年第二次 | A | 股类别股东大会及 | 2023 | 年第二 | | 次 H | 股类别股东大会会议议案 6 | | | | | | | 议案一： ...

Financial Performance - The company reported a half-year revenue of RMB 1.2 billion, representing a 15% increase compared to the same period last year[1]. - The company's revenue for the first half of 2023 was CNY 25,907,807.50, a decrease of 95.89% compared to CNY 629,790,353.02 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2023 was a loss of CNY 841,429,076.81, compared to a profit of CNY 12,238,427.20 in the previous year, representing a decrease of 6,975.30%[19]. - The net cash flow from operating activities was a negative CNY 737,403,150.66, a 39.23% improvement from a negative CNY 1,213,518,523.05 in the same period last year[19]. - The total assets decreased by 13.70% to CNY 9,897,271,179.30 from CNY 11,468,958,286.71 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 12.38% to CNY 5,912,488,550.94 from CNY 6,748,089,902.12 at the end of the previous year[19]. - The basic earnings per share for the first half of 2023 was CNY -3.41, a decrease of 6,920.00% compared to CNY 0.05 in the same period last year[20]. - The diluted earnings per share also stood at CNY -3.41, reflecting the same significant decline as the basic earnings per share[20]. - The company reported a net profit after deducting non-recurring gains and losses of CNY -892,960,573.30, compared to CNY -56,768,490.38 in the previous year, marking an increase of 1,472.99%[19]. Research and Development - Research and development expenses increased by 25% to RMB 300 million, focusing on new vaccine technologies[1]. - The R&D expenditure as a percentage of revenue was 1,310.33%, an increase of 1,258.53 percentage points from 51.80% in the previous year[20]. - The company has developed five major technology platforms for vaccine research, showcasing advanced capabilities in viral vector vaccines, synthetic vaccines, protein structure design, mRNA technology, and formulation techniques[51][52][53][54][55]. - The company is focused on developing vaccines for significant clinical needs, including meningococcal, COVID-19, pertussis, pneumonia, tuberculosis, and shingles[25]. - The company has established a comprehensive vaccine R&D platform, securing over 30 invention patents and publishing in renowned medical journals[66]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by the end of 2024[1]. - A strategic partnership was announced with a leading pharmaceutical company to enhance distribution channels, expected to increase sales by 15%[1]. - The company is exploring potential acquisitions to strengthen its product portfolio, with a budget of RMB 500 million allocated for this purpose[1]. - The company is actively monitoring the evolution of COVID-19 variants to inform its vaccine development strategy[29]. - The company has initiated international expansion, establishing vaccine production bases in countries like Pakistan and Mexico for localized COVID-19 vaccine production[70]. Regulatory and Compliance - The implementation of the Vaccine Administration Law in China has introduced stricter regulations across various stages of vaccine production and distribution, promoting industry consolidation and scale efficiency[47]. - The company has not reported any major asset or equity sales during the reporting period[113]. - The company has committed to transparency in reporting any changes in shareholding by its directors and senior management[138]. - The company has established a framework for accountability in case of any violations of the commitments made regarding shareholding[138]. Environmental Initiatives - The company invested 3.9846 million CNY in environmental protection during the reporting period[126]. - The company reduced carbon emissions by 3,478.6 tons through various measures, including energy audits and upgrading equipment for energy efficiency[131]. - The company has established an environmental management system and has not faced any administrative penalties for environmental violations during the reporting period[129]. - The company is focusing on low-carbon production and green energy-saving development concepts, enhancing corporate culture around green practices[131]. Shareholder and Governance - The company has approved a three-year dividend return plan for shareholders from 2023 to 2025[117]. - The company has initiated an employee stock ownership plan for 2023, which was approved in the recent shareholder meeting[117]. - The company has authorized the board to repurchase H shares and A shares, indicating a strategy to enhance shareholder value[118]. - The company has committed to compensating investors for any losses incurred due to unfulfilled commitments[173]. Financial Health and Risks - The company faces risks related to core competitiveness, operational challenges, and financial risks due to the competitive nature of the vaccine industry and potential market changes[90][91][92]. - The company recorded an asset impairment loss of ¥711,717,561.04, an increase of 615,101,003.49 compared to the same period last year, primarily due to impairment provisions for inventory and long-term assets[102]. - The total amount of guarantees provided by the company during the reporting period (excluding guarantees to subsidiaries) is 790,000,000.00 RMB[187]. - The total guarantee balance at the end of the reporting period (excluding guarantees to subsidiaries) is 392,115,088.37 RMB, which accounts for 6.57% of the company's net assets[187].

Financial Performance - For the six months ended June 30, 2023, the revenue was RMB 21,086 thousand, a decrease of 96.7% compared to RMB 629,790 thousand in the same period of 2022[8]. - The operating loss for the same period was RMB 1,342,432 thousand, an increase of 714.6% from RMB 164,800 thousand in the previous year[8]. - The loss before income tax was RMB 1,283,335 thousand, representing a significant increase of 2,988.3% compared to RMB 41,555 thousand in 2022[8]. - Total comprehensive loss for the period was RMB 1,282,024 thousand, a decline of 8,091.2% from a profit of RMB 16,043 thousand in the prior year[8]. - Basic and diluted loss per share was RMB (3.4098), a decrease of 6,988.5% from earnings of RMB 0.0495 per share in 2022[8]. - The company recorded a revenue of approximately RMB 21.1 million for the six months ended June 30, 2023, a significant decrease from RMB 629.8 million for the same period in 2022, primarily due to reduced demand for COVID-19 vaccine products and a provision for expected returns of RMB 237.1 million[40]. - The company reported a net loss of RMB 841,429 thousand for the six months ended June 30, 2023, compared to a net loss of RMB 1,282,024 thousand for the same period in 2022, indicating an improvement of approximately 34.4%[121]. Assets and Liabilities - As of June 30, 2023, total assets were RMB 9,897,272 thousand, down 13.7% from RMB 11,468,960 thousand at the end of 2022[10]. - Total equity decreased by 17.6% to RMB 5,969,259 thousand from RMB 7,245,602 thousand at the end of 2022[10]. - Non-current assets increased by 6.2% to RMB 3,969,248 thousand from RMB 3,738,775 thousand at the end of 2022[10]. - The company’s total liabilities decreased to RMB 3,928,013 thousand as of June 30, 2023, from RMB 4,223,358 thousand as of December 31, 2022, a decrease of approximately 7.0%[119]. - The company’s borrowings decreased to RMB 2,204,910 thousand as of June 30, 2023, from RMB 2,453,585 thousand as of December 31, 2022, a reduction of about 10.1%[119]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[11]. - The company has a broad vaccine pipeline targeting over ten disease areas, with five commercialized products currently[17]. - The company aims to address unmet medical needs globally with innovative vaccines, including mRNA COVID-19 vaccines and other candidates in clinical development[17]. - The company has initiated Phase III clinical trials for the DTcP vaccine for infants as of August 2023, with expectations to start the new drug application process in 2025[24]. - The company has launched Phase I clinical trials for the Tdcp vaccine for adolescents and adults, with approval received in June 2023, targeting populations aged 6 and above[26]. Market and Product Development - The company has received approval for the commercialization of the meningococcal vaccines Meinaixi® and Manhaixin®, with Meinaixi® being the best bivalent meningococcal vaccine in China and Manhaixin® being the first MCV4 vaccine approved in the country[17]. - The recombinant COVID-19 vaccine Kweisha® has received emergency use authorization overseas and conditional marketing approval in China as of June 30, 2023[20]. - Kweisha® has been widely administered as a booster vaccine in China since September 2022, with emergency use authorizations granted in Morocco and Indonesia[20]. - The company has established a comprehensive commercial operation center to implement marketing strategies for Manhaixin®[17]. - The company is actively expanding its marketing system and has identified key vaccination points and opinion leaders across China to promote its products, including the meningococcal vaccine[37]. Financial Position and Cash Flow - Cash and bank balances decreased by 29.6% from approximately RMB 3,394.8 million as of December 31, 2022, to approximately RMB 2,389.2 million as of June 30, 2023, attributed to reduced sales revenue and cash outflows from operating activities[69]. - Operating cash flow for the six months ended June 30, 2023, was a net outflow of RMB 753,907 thousand, an improvement from a net outflow of RMB 1,215,901 thousand in the same period of 2022[123]. - The company reported financial income of RMB 59,097 thousand for the period, down from RMB 123,245 thousand in the previous year, indicating a decrease of about 52.00%[116]. Corporate Governance - The company has adopted the corporate governance code and believes it has complied with all applicable provisions during the reporting period, except for the separation of the roles of Chairman and CEO, which are both held by Dr. Yu[80]. - The Audit Committee, consisting of three independent non-executive directors, reviewed the interim financial results for the six months ending June 30, 2023, and found them to comply with applicable accounting standards[84]. - The independent auditor, Deloitte, reviewed the interim financial information in accordance with the Hong Kong Institute of Certified Public Accountants' standards[85]. - The company will continue to review the effectiveness of its corporate governance structure, including the potential separation of the roles of Chairman and CEO[80]. Shareholder Information - As of June 30, 2023, Dr. Yu holds 34,598,400 H shares (13.98%) and 42,579,625 A shares (17.21%), representing approximately 26.08% and 37.10% of the respective classes of shares[89]. - The company did not recommend the payment of an interim dividend for the reporting period, consistent with the previous year[86]. - The company has repurchased 683,748 A-shares at a total cost of approximately RMB 150.2 million, with 277,650 shares allocated for the employee stock ownership plan as of June 30, 2023[108]. Impairment and Provisions - The group recognized an impairment loss of approximately RMB 325,401,000 for property, plant, and equipment as of June 30, 2023[142]. - The company recognized impairment losses of RMB 332,846,000 for inventory and RMB 325,401,000 for property, plant, and equipment related to COVID-19 vaccine products[127]. - The company adjusted the estimated future sales returns for sold products, resulting in a revenue adjustment of RMB 237,131,000 for the six months ended June 30, 2023[127]. Future Outlook - The company aims to enhance its capital efficiency and market competitiveness through strategic allocation of IPO proceeds[98]. - The company anticipates using the remaining unutilized proceeds based on current and future market conditions and business needs[107]. - The company plans to invest approximately RMB 2,244.7 million in the Kangsino Innovative Vaccine Industrial Park project, with funding sources including unutilized proceeds from the A-share IPO[104].

康希诺生物股份公司 由于员工持股平台系公司控股股东、实际控制人之一朱涛先生的一致行动 人，根据中国证券监督管理委员会进一步规范股份减持行为的规定，并结合自身 关于公司控股股东、实际控制人的一致行动人 暨员工持股平台提前终止减持计划公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、减持计划的主要内容 2023 年 8 月 15 日，康希诺生物股份公司（以下简称"公司"）披露了《关 于公司控股股东、实际控制人的一致行动人暨员工持股平台减持股份计划公告》 （公告编号：2023-045）。 公司控股股东、实际控制人之一、执行董事、副总经理朱涛先生担任普通合 伙人的天津千益企业管理合伙企业（有限合伙）（以下简称"天津千益"）、天 津千睿企业管理合伙企业（有限合伙）（以下简称"天津千睿"）、天津千智企 业管理合伙企业（有限合伙）（以下简称"天津千智"，天津千益、天津千睿及 天津千智合称"员工持股平台"）计划通过集中竞价、大宗交易方式减持其所持 有的公司股份合计不超过 4,910,000 股，拟减持股份占公司总股本的比例约为 1 ...

董事會會議延期 香港，2023年8月28日 茲提述康希諾生物股份公司（「本公司」）日期為2023年8月16日之通告，內容有關 本公司董事（「董事」）會（「董事會」）會議將於2023年8月28日（星期一）舉行，藉 以（其中包括）考慮及批准本公司及其附屬公司截至2023年6月30日止六個月的中 期業績（「二零二三年中期業績」）及其刊發佈。 於本通告日期，董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博士、朱 濤博士、Dongxu QIU博士及王靖女士；非執行董事林亮先生、梁頴宇女士及肖治 先生，以及獨立非執行董事韋少琨先生、辛珠女士、桂水發先生及劉建忠先生。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 董事會謹此宣佈，批准二零二三年中期業績及其刊發佈的董事會會議將延期至 2023年8月30日（星期三）舉行。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號 ...

证券代码：688185 证券简称：康希诺 公告编号：2023-047 康希诺生物股份公司 自愿披露关于全资子公司对外投资的公告 投资金额：8,573,877 马来西亚令吉（以下简称"RM"）（根据认购协议签 署日中国人民银行公布的汇率，约合人民币 13,338,950.17 元）。对应标的公司 43,968,600 股股份，约占认购协议签署之日标的公司已发行总股本 10%。 相关风险提示：本次投资事项不构成关联交易，亦不构成《上市公司重 大资产重组管理办法》《科创板上市公司重大资产重组特别规定》规定的重大资 产重组情形。 一、对外投资概述 （一）对外投资的基本情况 公司基于自身战略发展规划、与标的公司之间的业务协同性以及对标的公司 投资价值的判断，为拓展东南亚市场，拟由康希诺香港与标的公司签署认购协议， 约定以 0.1950 RM/股（根据认购协议签署日中国人民银行公布的汇率，约合 0.3034 人民币元/股）的对价取得标的公司 43,968,600 股股份，约占认购协议签 署之日标的公司已发行总股本 10%。 （二）对外投资的决策与审批程序 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 ...

证券代码：688185 证券简称：康希诺 公告编号：2023-046 康希诺生物股份公司 自愿披露关于重组新型冠状病毒疫苗（5型腺病毒载体） 获得印度尼西亚清真认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 概述 康希诺生物股份公司（以下简称"公司"）于近日收到印度尼西亚（以下简称 "印尼"）乌拉玛委员会食品、药品及化妆品评估机构（Assesment Institute for Foods, Drugs and Cosmetics of Majelis Ulama Indonesia）授予重组新型冠状病毒疫苗（5 型腺病毒载体）克威莎®（以下简称"克威莎®"）的清真认证。 印尼约 87%的人口信奉伊斯兰教，是世界上穆斯林人口最多的国家。公开数 据显示，2022 年印尼共有 2.78 亿人口，人口总数位居全球第四位。根据印尼政 府的规定，印尼市场上的药品须经由清真产品保证机构（Halal Product Assurance Body）认可取得清真认证。此次获得清真认证，标志着克威莎®可以进入全球互 认的穆斯 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （股份代號：6185） 董事會會議日期 康希諾生物股份公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，董事會 會議將於2023年8月28日（星期一）舉行，藉以（其中包括）考慮及批准本公司及其 附屬公司截至2023年6月30日止六個月的中期業績及其刊發佈，以及建議派發中 期股息（如有）。 承董事會命 康希諾生物股份公司 Xuefeng YU 董事長 （於中華人民共和國註冊成立的股份有限公司） 香港，2023年8月16日 於本通告日期，董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博士、朱 濤博士、Dongxu QIU博士及王靖女士；非執行董事林亮先生、梁頴宇女士及肖治 先生，以及獨立非執行董事韋少琨先生、辛珠女士、桂水發先生及劉建忠先生。 ...

证券代码：688185 证券简称：康希诺 公告编号：2023-045 康希诺生物股份公司 关于公司控股股东、实际控制人的一致行动人 暨员工持股平台减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 公司控股股东、实际控制人之一、执行董事、副总经理朱涛先生担任普 通合伙人的天津千益企业管理合伙企业（有限合伙）（以下简称"天津千益"）、 天津千睿企业管理合伙企业（有限合伙）（以下简称"天津千睿"）、天津千智企业 管理合伙企业（有限合伙）（以下简称"天津千智"，天津千益、天津千睿及天津千 智合称"员工持股平台"）分别持有公司股份 3,474,600 股、3,299,475 股、1,207,150 股，占公司总股本 1.40%、1.33%、0.49%，为其于公司首次公开发行前取得的股 份，且已于 2023 年 8 月 14 日起上市流通。 减持计划的主要内容：天津千益、天津千睿、天津千智计划通过集中竞 价、大宗交易方式减持其所持有的公司股份合计不超过 4,910,000 股，拟减持股 份占 ...